Bachmann-Bupp syndrome is an ultra-rare genetic disorder caused by gain-of-function variants in the ODC1 gene. A decades-old drug, DFMO, targets the cause directly.
Off-label, not FDA-approved for BABS
DFMO (eflornithine) blocks the overactive enzyme that causes BABS. Published reports describe hair regrowth, better muscle tone, and developmental gains.
Bachmann-Bupp syndrome (BABS) is an ultra-rare genetic disorder caused by gain-of-function variants in the ODC1 gene, which makes the ODC1 enzyme overactive.
Because ODC1 isn’t included on standard genetic panels, the condition is likely underdiagnosed. Children are typically identified after whole exome or genome sequencing. About 20 patients had been diagnosed worldwide as of January 2026.
ODC1 isn’t on standard genetic panels. If BABS is suspected, whole exome or genome sequencing is the usual route to a diagnosis.
DFMO (eflornithine)
Off-label, not FDA-approved for BABSDFMO inhibits the overactive ODC1 enzyme, directly targeting the cause of the disease. It has historically been used for African sleeping sickness and is FDA-approved to help prevent recurrence of neuroblastoma.
Every Cure is collaborating with the physician-scientists who first identified BABS, Dr. André Bachmann (Michigan State University) and Dr. Caleb Bupp (Corewell Health), to ensure all patients with BABS are able to benefit from this potentially life-changing treatment.
DFMO is not FDA-approved for BABS. To date it has been used off-label under physician supervision.
Dr. Bupp and colleagues report a new ODC1 variant in a girl with developmental delay and alopecia. Source
A case report in eLife describes repurposing eflornithine for a child with BABS. Source
Pediatric Dermatology reports dermatological improvement in patients treated with DFMO. Source
A new collaboration aims to bring DFMO to more patients and make sure no patient goes undiagnosed. Source
3 papers
Bupp CP, VanSickle EA, Michael J, Schultz CR, Nguyen K, Hoefer M, et al.
American Journal of Medical Genetics Part C, 2025
Summarizes treatment experience with eflornithine in BABS and what it could mean for related polyamine disorders.
Afrin A, Afshan TS, VanSickle EA, Michael J, Laarman RL, Bupp CP
Pediatric Dermatology, 2023;40(3):528–531
Patients treated with DFMO showed improvement in hair and skin symptoms.
Rajasekaran S, Bupp CP, Leimanis-Laurens M, Shukla A, Russell C, Junewick J, et al.
eLife, 2021
The first report of a child with BABS treated with eflornithine.